- Home
- CLGN vs YI Comparison
CLGN vs YI Comparison
Compare CLGN & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLGN
- YI
- Stock Information
- Founded
- CLGN 2004
- YI 2010
- Country
- CLGN Israel
- YI China
- Employees
- CLGN N/A
- YI N/A
- Industry
- CLGN Industrial Specialties
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- CLGN Health Care
- YI Consumer Staples
- Exchange
- CLGN Nasdaq
- YI Nasdaq
- Market Cap
- CLGN 33.8M
- YI 38.0M
- IPO Year
- CLGN N/A
- YI N/A
- Fundamental
- Price
- CLGN N/A
- YI N/A
- Analyst Decision
- CLGN Strong Buy
- YI
- Analyst Count
- CLGN 2
- YI 0
- Target Price
- CLGN $11.50
- YI N/A
- AVG Volume (30 Days)
- CLGN 257.5K
- YI 25.4K
- Earning Date
- CLGN 11-26-2025
- YI 11-26-2025
- Dividend Yield
- CLGN N/A
- YI N/A
- EPS Growth
- CLGN N/A
- YI N/A
- EPS
- CLGN N/A
- YI N/A
- Revenue
- CLGN $2,402,000.00
- YI $1,979,883,442.00
- Revenue This Year
- CLGN $1,617.28
- YI N/A
- Revenue Next Year
- CLGN $83.54
- YI N/A
- P/E Ratio
- CLGN N/A
- YI N/A
- Revenue Growth
- CLGN 248.62
- YI N/A
- 52 Week Low
- CLGN $1.31
- YI $4.15
- 52 Week High
- CLGN $4.99
- YI $11.35
- Technical
- Relative Strength Index (RSI)
- CLGN 45.87
- YI 34.03
- Support Level
- CLGN $2.11
- YI $4.48
- Resistance Level
- CLGN $2.44
- YI $4.86
- Average True Range (ATR)
- CLGN 0.22
- YI 0.24
- MACD
- CLGN -0.03
- YI 0.05
- Stochastic Oscillator
- CLGN 23.36
- YI 31.96
About CLGN CollPlant Biotechnologies Ltd
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.